Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Similar documents
Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

List of Designated High-Cost Drugs

National Cancer Drugs Fund List - Approved

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

April May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

Prior Authorization Approval Guidelines. May, 2017

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

ORAL ONCOLOGY CRITERIA

NB Drug Plans Formulary Update

Specialty Pipeline Update

NBPDP Formulary Update

Specialty Pipeline Update

Quarterly Report on Completed Drug Submission Reviews

ORAL ONCOLOGY CRITERIA

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

Specialty Pipeline Update

2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

Biologics for Autoimmune Diseases

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

Prescription benefit updates Large group

April 2015 May SMC RECOMMENDED MEDICINES FOR USE Recommended for use within NHS Scotland April 2015 May 2015 Date SMC SMC Drug Name

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Pfizer Pipeline. November 8, 2012

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Cosentyx. Cosentyx (secukinumab) Description

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

NICE TA Adherence Check List

ACTEMRA (tocilizumab)

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Pfizer Pipeline. August 9, 2012

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

Medicare Part C Medical Coverage Policy

Immune Modulating Drugs Prior Authorization Request Form

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

CIMZIA (certolizumab pegol)

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

Special Authorization

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

NB Drug Plans Formulary Update

Disclosure. Outline New Info on

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

Aetna Better Health. Specialty Drug Program

Cimzia. Cimzia (certolizumab pegol) Description

Pfizer Pipeline. May 10, 2012

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Specialty Pipeline Update

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Keytruda. Keytruda (pembrolizumab) Description

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16

Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

I. Diagnosis of the cancer type in CUP

Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG

Commercial Formulary and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016

Summary of Strategic Competitive Analysis and Publication Planning

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

NB Drug Plans Formulary Update

04 September 2017 Page 1 of 6

Criteria for Medical Benefit Drugs Requiring Clinical Review

Cancer Therapy Update in 2017

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Keytruda. Keytruda (pembrolizumab) Description

Pharmacy and Medical Guideline Updates

Corporate Medical Policy

JULY 2016 PBAC MEETING POSITIVE RECOMMENDATIONS LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION

Using virtual populations to solve drug development problems. Iain Gardner Head of Translational DMPK Science SIMCYP

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

Transcription:

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of August 31, 2018 235 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic Name) Abilify Maintena (aripiprazole long acting injection) Abraxane (nab-paclitaxel) Actemra (tocilizumab) SC Actikerall (fluorouracil and salicylic acid)* Adcetris (brentuximab) Adempas (riociguat) Advair (salmeterol xinafoate/fluticasone propionate) Afinitor (everolimus) Afinitor (everolimus) Alimta (pemetrexed) Anoro Ellipta (umeclidinium bromide/vilanterol trifenatate) Aptiom (eslicarbazepine) Arnuity Ellipta (fluticasone furoate) Aubagio (teriflunomide) Avastin (bevacizumab) Avastin (bevacizumab) Avastin (bevacizumab) Basaglar (insulin glargine) Blincyto (blinatumomab) Bosulif (bosutinib) Botox (onabotulinumtoxin A) Brenzys (etanercept) Breo Ellipta (fluticasone furoate/vilanterol) Breo Ellipta (fluticasone furoate/vilanterol) Brilinta (ticagrelor) Cimzia (certolizumab) Caprelsa (vandetanib) Cosentyx (secukinumab) Cosentyx (secukinumab) Cosentyx (secukinumab) Cotellic (cobimetinib) Cyramza (ramucirumab) Indication/Use Please refer to individual jurisdictions for specific reimbursement criteria Used for the maintenance treatment of schizophrenia Used first-line to treat locally advanced unresectable or metastatic adenocarcinoma of the pancreas Used to treat hyperkeratotic actinic keratosis Used to treat lymphoma Used to treat chronic thromboembolic pulmonary hypertension and asthma Used to treat pancreatic neuroendocrine tumours, and to treat breast cancer Used to treat neuroendocrine tumours of gastrointestinal or lung origin Used to treat lung cancer (new indication) Used to treat seizures Used to treat asthma Used to treat persistent, recurrent, or metastatic cervical cancer Used to treat epithelial ovarian cancer Used to treat genitourinary platinum-resistant ovarian cancer Used to treat metastatic colorectal cancer Used to treat type 1 and 2 diabetes mellitus Used to treat acute lymphoblastic leukemia Used to treat chronic myelogenous leukemia (CML) Used to treat multiple indications and ankylosing spondylitis Used for the treatment of asthma Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Used to treat ankylosing spondylitis, psoriatic arthritis Used to treat medullary thyroid cancer Used to treat moderate to severe plaque psoriasis Used to treat psoriatic arthritis Used to treat ankylosing spondylitis Used to treat gastrointestinal metastatic gastric cancer or gastroesophageal junction adenocarcinoma

Daklinza (daclatasvir) Diacomit (stiripentol) Dificid (fidaxomicin) Duaklir Genuair (aclidinium bromide/formoterol fumarate dehydrate) Dysport Therapeutic (abobotulinumtoxin A) Dysport Therapeutic (abobotulinumtoxin A) Used to treat chronic Hepatitis C infection Used in patients with severe myoclonic epilepsy in infancy Used to treat Clostridium difficile (COPD) Used to treat cervical dystonia Used to treat upper limb spasticity Effient (prasugrel) Used with ASA to prevent atherothrombotic events in patients with acute coronary syndrome Elelyso (taliglucerase alfa) Used to treat Gaucher Disease Type 1 Eliquis (apixaban) Eliquis (apixaban) Enstilar (calcipotriol/betamethasone)* Entresto (sacubitril/valsartan) Entyvio (vedolizumab) Entyvio (vedolizumab) Epclusa (sofosbuvir/velpatasvir) Erelzi (etanercept) Erivedge (vismodegib) Esbriet (pirfenidone) Esbriet (pirfenidone) Eylea (aflibercept) Eylea (aflibercept) Fabrazyme (agalsidase beta) Fabrazyme (agalsidase beta) Ferriprox (deferiprone) Fibristal (ulipristal acetate) Firazyr (icatibant) Forxiga (dapagliflozin) Galafold (migalastat)* Galexos (simeprevir) Gazyva (obinutuzumab) Gazyva (obinutuzumab) Genvoya (elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide) Gilenya (fingolimod) Giotrif (afatinib) Giotrif (afatinib) Glatect (glatiramer acetate) Grastofil (filgrastim) Halaven (eribulin) Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism Used to treat psoriasis Used to treat heart failure Used to treat ulcerative colitis Used to treat Crohn s disease Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis Used to treat metastatic basal cell carcinoma Used to treat idiopathic pulmonary fibrosis Used to treat idiopathic pulmonary fibrosis Used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and/or macular edema secondary to central retinal vein occlusion (CRVO) Used to treat macular edema secondary to branch retinal vein occlusion Used to treat Fabry disease Used to treat Fabry disease Used to treat Transfusional Iron Overload Used to treat uterine fibroids Used to treat acute attacks of hereditary angioedema Used to treat Fabry Disease Used to treat chronic hepatitis C Genotype 1 infection Used to treat chronic lymphocytic leukemia Used to treat follicular lymphoma Used to treat HIV-1 Infection Used to treat advanced non-small cell lung cancer Used to treat advanced non-small cell lung cancer Used for prevention or treatment of neutropenia in various indications Used to treat breast cancer

Harvoni (sofosbuvir/ledipsavir) Harvoni (sofosbuvir/ledipsavir) Hemangiol (propranolol) Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) Humira (adalimumab) Humira (adalimumab) Ibavyr (ribavirin) Ibrance (palbociclib) Iclusig (ponatinib) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Imbruvica (ibrutinib) Incruse Ellipta (umeclidinium) Inflectra (infliximab) Inflectra (infliximab) Inlyta (axitinib) Inspiolto Respimat (tiotropium/olodaterol) Inspra (eplerenone) Invega Trinza (paliperidone palmitate) Invokana (canagliflozin) Istodax (romidepsin) Jadenu (deferasirox) Jakavi (ruxolitinib) Jakavi (ruxolitinib) Janumet (sitagliptin/metformin) Januvia (sitagliptin) Jardiance (empagliflozin) Jetrea (ocriplasmin) Kadcyla (trastuzumab emtansine) Kalydeco (ivacaftor) Keytruda (pembrolizumab) Keytruda (pembrolizumab) Keytruda (pembrolizumab) Kuvan (saproterin) Kyleena (levonorgestrel) Kyprolis (carfilzomib) Kyprolis (carfilzomib) Lancora (ivabradine)* Lemtrada (alemtuzumab) Lenvima (lenvatinib) Used to treat infantile hemangioma Used to treat ulcerative colitis Used to treat hidradenitis suppurativa Used to treat advanced breast cancer Used to treat Chronic Myeloid Leukemia (CML)/ Acute Lymphoblastic Leukemia Used to treat chronic lymphocytic leukemia or small lymphocytic leukemia Used to treat relapsed/refractory Mantle Cell Lymphoma Used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma (COPD), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis Used to treat ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn s disease and Ulcerative Colitis Used to treat metastatic renal cell carcinoma (COPD) Used to treat New York Heart Association (NYHA) class II systolic heart failure Used to treat schizophrenia Used to treat relapsed/refractory peripheral T-cell lymphoma Used to treat chronic iron overload Used to treat intermediate to high risk myelofibrosis Used to treat polycythemia vera Used to treat symptomatic vitreomacular adhesion Used to treat HER-2 positive metastatic breast cancer Used to treat cystic fibrosis Used to treat non-small cell lung cancer (second line or beyond) Used to treat non-small cell lung cancer (first line) Used to treat phenylketonuria Used for the prevention of pregnancy Used to treat multiple myeloma Used to treat multiple myeloma (relapsed) Used to treat NYHA class II or III heart failure Used to treat thyroid cancer

Lodalis (colesevelam) Lynparza (olaparib) Mekinist (trametinib) Metadol-D (methadone hydrochloride) Metoject (methotrexate) Mictoryl (propiverine) Mifegymiso (mifepristone/misoprostol) Mozobil (plerixafor) Mozobil (plerixafor) Myrbetriq (mirabegron) Narcan (naloxone hydrochloride) Neupro (rotigotine) Nucala (mepolizumab) Ocaliva (obeticholic acid) Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) Ofev (nintedanib) Onbrez (indacaterol) Onglyza (saxagliptan) Oralair (grass pollen allergen extract) Orencia (abatacept) Perjeta (pertuzumab) Pheburane (sodium phenylbutyrate) Plegridy (PegIFN beta-1a) Pomalyst (pomalidomide) Pomalyst (pomalidomide) Second letter of intent Praluent (alirocumab)* Pradaxa (dabigatran) Prezcobix (darunavir/cobicistat) Procysbi (cysteamine bitartrate) Prolia (denosumab) Ravicti (glycerol phenylbutyrate) Rebif (interferon beta-1a) Remicade (infliximab) Renflexis (infliximab) Repatha (evolocumab) Used to treat hypercholesterolemia Used to treat ovarian cancer Used to treat opioid dependence Used to treat overactive bladder (paediatric) Used for the medical termination of pregnancy Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Used in combination with granulocyte colony-stimulating factor to support treatment for non-hodgkin lymphoma and multiple myeloma Used to treat overactive bladder Used to treat opioid overdose Used to treat Parkinson's disease Used to treat severe eosinophilic asthma Used to treat primary biliary cholangitis Used to treat idiopathic pulmonary fibrosis Used as a bronchodilator for chronic obstructive pulmonary disease Used to treat advanced or metastatic non-small cell lung cancer Used to treat advanced or metastatic renal cell carcinoma Used to treat squamous cell carcinoma of the head and neck (SCCHN) Used to treat allergic rhinitis with or without conjunctivitis Used to treat breast cancer Used to treat urea cycle disorders (RRMS) Used to treat multiple myeloma Used to treat multiple myeloma Used for lowering of low density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH) Used to prevent strokes in patients with atrial fibrillation Used to treat nephropathic cystinosis Used to treat osteoporosis Used to treat urea cycle disorders Used for clinically isolated syndrome Used to treat multiple indications including rheumatoid arthritis, ulcerative colitis and Crohn s disease, ankylosing spondylitis, adult Crohn s disease, pediatric Crohn s disease, fistulising Crohn s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Used to treat primary hyperlipidemia and mixed dyslipidemia

Replagal (agalsidase alfa) Replagal (agalsidase alfa) Revestive (teduglutide)* Revlimid (lenalidomide) Revlimid (lenalidomide) Rituxan SC (rituximab) Rituxan SC (rituximab)* Rydapt (midostaurin) Seebri Breezhaler (glycopyrronium bromide) Simbrinza (brinzolamide/brimonidine) Simponi (golimumab) SC Soliris (eculizumab) Sovaldi (sofosbuvir) Sovaldi (sofosbuvir) Spiriva Respimat (tiotropium) Stivarga (regorafenib) Stivarga (regorafenib) Strensiq (asfotase alfa) Stribild (elvitegravir/cobicistat/ emtricitabine/tenofovir) Sunvepra (asunaprevir) Sutent (sunitinib) Sylvant (siltuximab) Tafinlar (darafenib) Tafinlar (dabrafenib) and Mekinist (tramatinib) Tagrisso (osimertinib) Taltz (Ixekizumab) Tecfidera (dimethyl fumarate) Tivicay (dolutegravir) Tobi Podhaler (tobramycin) Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin) Treanda (bendamustine) Tresiba (insulin degludec) Triumeq (dolutegravir/abacavir/lamivudine) Tudorza Genuair (aclidinium bromide) Tysabri (natalizumab) Ultibro (indacaterol/glycopyrronium) Uptravi (selexipag) Valtrex (valacyclovir) Used to treat Fabry Disease Used to treat Fabry Disease Used to treat short bowel syndrome (SBS) Used for maintenance treatment in multiple myeloma after a stem cell transplant Used to treat newly diagnosed multiple myeloma Used to treat multiple indications Used to treat chronic lymphocytic leukemia Used to treat Acute Myeloid Leukemia Used to treat glaucoma and ocular hypertension Used to treat ulcerative colitis Used to treat paroxysmal nocturnal hemoglobinuria Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat metastatic and/or unresectable gastrointestinal stromal tumours (GIST) Used to treat pediatric-onset hypophosphatasia in antiretroviral treatment-naïve adult patients Used to treat chronic Hepatitis C Used to treat pancreatic neuroendocrine tumours Used to treat multicentric Castleman s disease (in combination) Used to treat locally advanced or metastatic EGFR T790M mutationpositive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy Used to treat moderate to severe plaque psoriasis Used to treat multiple sclerosis Used for the management of cystic fibrosis patients with chronic pulmonary Pseuodomonas aeruginosa infections Used to treat non-hodgkin lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia Used to treat type 1 and type 2 diabetes mellitus Used in management of chronic obstructive pulmonary disease (COPD) Used to treat pulmonary arterial hypertension Used to treat specific viral infections

Vectibix (panitumumab) Vosevi (sofosbuvir velpatasvir voxilaprevir) Votrient (pazopanib) Used to treat metastatic colorectal cancer Used to treat metastatic renal cell carcinoma Votrient (pazopanib) Used to treat metastatic renal cell carcinoma VPRIV (velaglucerase) Used to treat Gaucher Disease Type 1 Xalkori (crizotinib) Xalkori (crizotinib) Xarelto (rivaroxaban) Xarelto (rivaroxaban) Xeljanz (tofacitinib) XigDuo (dapagliflozin/metformin hydrochloride) Xolair (omalizumab) Xtandi (enzalutamide) Xtandi (enzulatamide) Yervoy (ipilimumab) Yervoy (ipilimumab) Zaxine (rifaximin) Used to treat advanced non-small cell lung cancer (second-line) Used to treat advanced non-small cell lung cancer (first-line) New indication for treatment of venous thromboembolic events and prevention of recurrent deep vein thrombosis and pulmonary embolism. Used to prevent strokes in patients with atrial fibrillation, and to prevent deep vein thrombosis Used to treat type 2 diabetes mellitus Used to treat chronic idiopathic urticaria Used to treat first-line metastatic castrate resistant prostate cancer (before chemotherapy) Used to treat castrate resistant prostate cancer (after chemotherapy) Used for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma Used for the second-line treatment of adult patients with unresectable or metastatic melanoma Used to treat hepatic encephalopathy Zepatier (elbasvir grazoprevir) Used for the treatment of Hepatitis C (genotype 1, 4) Zydelig (idelalisib) Zykadia (ceritinib) Zytiga (abiraterone) Used to treat relapsed chronic lymphocytic leukemia (CLL) Used to treat ALK+ non-small cell lung cancer Used to treat prostate cancer 26 drug negotiations were closed as agreements were not reached: Abilify (aripiprazole) Used for the treatment of schizophrenia and related psychotic disorders Adempas (riociguat) Used to treat pulmonary arterial hypertension Brilinta (ticagrelor) Used with ASA to prevent atherothrombotic events with history of myocardial infarction Butrans (buprenorphine) Used to treat persistent pain of moderate intensity Byetta (exenatide) Campral (acamprosate calcium) Used for maintenance of alcohol abstinence Caprelsa (vandetanib) Used to treat medullary thyroid cancer Cerdelga (eliglustat) Used to treat Gaucher Disease Type 1 Cerezyme (imiglucerase) Used to treat Gaucher Disease Type 1 Daklinza (daclatasvir) Used to treat chronic Hepatitis C Descovy (emtricitabine/tenofovir alafenamide) Invokamet (canagliflozin/metformin Used to treat type 2 diabetes mellitus hydrochloride) Kalydeco (ivacaftor) Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation Kevzara (sarilumab)

Methadose (methadone) Mictoryl (propiverine) Opsumit (macitentan) Otezla (apremilast) Otezla (apremilast) Rosiver (ivermectin) Rosiver (ivermectin) Simponi (golimumab) IV Soliris (eculizumab) Strensiq (asfotase alfa) Technivie (ombitasvir/paritaprevir/ ritonavir) Victoza (liraglutide) Used to treat opioid dependence Used to treat overactive bladder Used to treat pulmonary arterial hypertension Used to treat moderate to severe plaque psoriasis Used to treat psoriatic arthritis Used to treat rosacea Used to treat rosacea Used to treat ahus Used to treat hypophosphatasia Used for the treatment of Hepatitis C (genotype 4) ** A completed pan-canadian negotiation refers to those for which a Letter of Intent (document which outlines the agreed upon terms and conditions for listing) has been signed between the lead jurisdiction for the negotiation and the manufacturer OR negotiations have been closed without a Letter of Intent. The initial nine products negotiated through the pcpa. * New negotiations that have been completed since last update on July 31, 2018. www.canadaspremiers.ca